These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 1515241)
1. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241 [TBL] [Abstract][Full Text] [Related]
2. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435 [TBL] [Abstract][Full Text] [Related]
3. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164 [TBL] [Abstract][Full Text] [Related]
4. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486 [TBL] [Abstract][Full Text] [Related]
5. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696 [TBL] [Abstract][Full Text] [Related]
7. Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns. Dookeran KA; Rye PD; Dearing SJ; Walker RA J Pathol; 1993 Oct; 171(2):123-9. PubMed ID: 8283349 [TBL] [Abstract][Full Text] [Related]
8. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast]. Sánchez Salmón A; Argibay S; Arias JI; Ruibal A Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785 [TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay]. Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210 [TBL] [Abstract][Full Text] [Related]
10. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]. Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545 [TBL] [Abstract][Full Text] [Related]
11. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of pS2 mRNA in breast cancer. Wysocki SJ; Iacopetta BJ; Ingram DM Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621 [TBL] [Abstract][Full Text] [Related]
13. Expression of pS2 protein in breast cancer. Crombach G; Ingenhorst A; Göhring UJ; Scharl A; Neuhaus W; Möbus V; Schaeffer HJ Arch Gynecol Obstet; 1993; 253(4):183-92. PubMed ID: 8161252 [TBL] [Abstract][Full Text] [Related]
14. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Henry JA; Piggott NH; Mallick UK; Nicholson S; Farndon JR; Westley BR; May FE Br J Cancer; 1991 Apr; 63(4):615-22. PubMed ID: 1850611 [TBL] [Abstract][Full Text] [Related]
15. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448 [TBL] [Abstract][Full Text] [Related]
16. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Hurlimann J; Gebhard S; Gomez F Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242 [TBL] [Abstract][Full Text] [Related]
17. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985 [TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677 [TBL] [Abstract][Full Text] [Related]
19. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959 [TBL] [Abstract][Full Text] [Related]
20. pS2 protein and steroid hormone receptors in invasive breast carcinomas. Koerner FC; Goldberg DE; Edgerton SM; Schwartz LH Int J Cancer; 1992 Sep; 52(2):183-8. PubMed ID: 1521907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]